| Generic name | Copanlisib |
| Brand name(s), other common name(s) | AliqopaTM |
| Drug type | Phosphatidylinositol-3-kinase (PI3K) inhibitor |
| How the drug is given | Intravenously (IV) |
Indications and Usage
Copanlisib is FDA approved for the treatment of adult patients with relapsed follicular lymphoma (FL) who have received at least two prior systemic therapies.
Side effects needing medical attention
High blood sugar levels (hyperglycemia), diarrhea, decreased general strength and energy, high blood pressure (hypertension), low levels of certain white blood cells (leukopenia, neutropenia), nausea, lower respiratory tract infections, and low levels of blood platelets (thrombocytopenia).
For information on how to manage the costs of drug therapy, please see Financial Support, or to speak with an Information Specialist, call (800) 955-4572.